RIPK1 and myeloid sarcoma: Many studies have reported that RIPK1 inhibitors present an opportunity to treat a range of human degenerative and inflammatory diseases, including colitis, dermatitis, traumatic brain injury, stroke, lysosomal storage diseases, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) [52, 53].